Collagen-based meniscus implants
A method for producing a collagen meniscus implant by obtaining a freshly excised non-human meniscus, rinsing it in an aqueous solution, drying the rinsed meniscus, shaping it to approximate in dimension an average-sized human meniscus, extracting non-collagenous material from the shaped meniscus, and sterilizing it, yielding a collagen meniscus implant containing at least 90% by weight of type I collagen, less than 0.5% by weight of glycosaminoglycan, and less than 600 ppm DNA. Also disclosed is a collagen meniscus implant prepared by the above method. Further provided is a biocompatible and bioresorbable porous implant for meniscus repair. The implant includes a three-dimensional network of collagen fibers oriented in a direction approximating the collagen fiber orientation of a human meniscus. The implant has a size and a contour substantially equivalent to a human meniscus, and has a chemical composition similar to the above-described collagen meniscus implant.
1 . A collagen meniscus implant produced by a method comprising steps including:
obtaining a freshly excised non-human meniscus, rinsing the non-human meniscus in an aqueous solution, drying the rinsed non-human meniscus,
machine shaping the dried non-human meniscus to the dimensions of an average-sized human meniscus,
extracting the machine shaped non-human meniscus to remove non-collagenous material,
and
sterilizing the extracted non-human meniscus, thereby forming the collagen meniscus implant,
wherein the collagen meniscus implant has a density of about 0.29 g/cm 3 , and contains at least 90% by weight of type I collagen, less than 0.2% by weight of glycosaminoglycan, and 81 to 91 ppm DNA; and
the method is free of any enzymatic digesting steps and oxidizing steps;
wherein the collagen meniscus implant comprises a surface, the surface having a plurality of pores;
wherein the collagen meniscus implant has a void volume of at least 60% of the total
implant volume;
wherein the collagen meniscus implant is biocompatible with a human patient; and wherein the collagen meniscus implant is bioresorbable and is stable in vivo after
implantation for a period of 6 to 12 months.
2 . The collagen meniscus implant of claim 1 , wherein the non-human meniscus is bovine meniscus.
3 . The collagen meniscus implant of claim 1 , wherein the pores have a size of about 10 μm to about 100 μm.
4 . The collagen meniscus implant of claim 3 , wherein the collagen meniscus implant pores are configured to allow fibrochondrocytes to migrate inside the implant after implantation to form an endogenous extracellular matrix that replaces the collagen meniscus implant.
5 . The collagen meniscus implant of claim 3 , wherein the collagen meniscus implant is configured to reduce rehabilitation time of a tom meniscus following implantation into the human patient.
6 . The collagen meniscus implant of claim 5 , wherein the collagen meniscus implant pores are configured to allow fibrochondrocytes to migrate inside the implant after implantation to form an endogenous extracellular matrix that replaces the collagen meniscus implant.
7 . A biocompatible and bioresorbable porous implant for meniscus repair, the implant comprising a sterilized three-dimensional network of collagen fibers derived from a non-human meniscus, wherein the collagen fibers are oriented in a direction as are the collagen fibers of a human meniscus, the implant has a density of about 0.29 g/cm 3 , has a plurality of pores having a void volume of at least 60% of the total implant volume and a size and a contour of a human meniscus, and the implant is at least 90% by weight of type I collagen, contains about 81 to 91 ppm DNA and less than 0.2% by weight of glycosaminoglycan, and is configured to be stable in vivo after implantation for a period of 6 to 12 months.
8 . The implant of claim 7 , wherein the implant is at least 95% by weight of type I collagen.
9 . The implant of claim 7 , wherein the pores have a size of about 10 μm to about 100 μm.
10 . The implant of claim 7 , wherein the non-human meniscus is bovine meniscus.
11 . A collagen meniscus implant
comprising: a non-human collagen source;
at least 90% by weight of type I collagen;
less than 0.2% by weight of
glycosaminoglycan; and about 81 to 91 ppm
DNA;
an outside surface providing a perimeter of the implant, the outside surface comprising pores having a size of 10 μm to 100 μm;
wherein the collagen meniscus implant has a density of about 0.29 g/cm 3 ,
wherein the collagen meniscus implant is configured for in vivo use in a human patient; wherein the collagen meniscus implant is configured to be stable in vivo for a period of
about 6 to 12 months; and
wherein the collagen meniscus implant pores are configured to allow fibrochondrocytes to migrate inside the implant after implantation to form an endogenous extracellular matrix that replaces the collagen meniscus implant.
12 . The collagen meniscus implant of claim 11 , wherein the collagen meniscus implant is configured to reduce rehabilitation time following implantation into a human patient.
13 . The collagen meniscus implant of claim 11 , wherein the implant is at least 95% by weight of type I collagen.
14 . The collagen meniscus implant of claim 11 , wherein the non-human collagen source is a bovine meniscus.
15 . The collagen meniscus implant of claim 14 , wherein the bovine meniscus is produced by a method comprising the steps of:
obtaining a freshly excised meniscus from a bovine source,
removing adherent tissues from the freshly excised meniscus to form a cleaned meniscus; rinsing the cleaned meniscus in an aqueous solution;
machining the rinsed meniscus to fit into a human
subject; drying the machined meniscus;
extracting the dried machined non-human meniscus to remove non-collagenous material;
and
sterilizing the extracted non-human meniscus, thereby forming the collagen meniscus
implant.
16 . The collagen meniscus implant of claim 11 , wherein the implant has a void volume of at least 60% of the total implant volume.
17 . The collagen meniscus implant of claim 11 , wherein the implant has been subject to a sterilization process.
18 . A collagen meniscus implant produced by a method comprising steps including:
obtaining a freshly excised meniscus from a non-human animal source,
removing adherent tissues from the freshly excised meniscus to form a cleaned meniscus; rinsing the cleaned meniscus in an aqueous solution;
machining the rinsed meniscus to fit into a human subject;
and drying the machined meniscus;
extracting the dried machined non-human meniscus to remove non-collagenous material;
and
sterilizing the extracted non-human meniscus, thereby forming the collagen meniscus
implant;
wherein the collagen meniscus implant comprises at least 90% by weight of type I collagen; wherein the collagen meniscus implant comprises less than 0.2% by weight of
glycosaminoglycan;
wherein the collagen meniscus implant has a density of about 0.29 g/cm 3 , wherein the collagen meniscus implant comprises about 81 to 91 ppm DNA; wherein the method lacks an enzymatic digesting step;
and
wherein the method lacks an oxidizing step.
19 . The collagen meniscus implant of claim 18 , wherein the non-human animal source is a bovine meniscus.
20 . A collagen meniscus implant comprising:
a non-human collagen source comprising at least 90% by weight of type I collagen; less than 0.2% by weight of glycosaminoglycan; and
about 81 to 91 ppm DNA;
wherein the collagen meniscus implant has a density of about 0.29 g/cm 3 ,
wherein a surface of the collagen meniscus implant comprises pores, the pores having a size of 10 μm to 100 μm;
wherein the collagen meniscus implant is configured for in vivo use in a human patient and to be stable in vivo for a period of about 6 to 12 months; and
wherein the collagen meniscus implant is configured to reduce rehabilitation time following implantation into a human patient.